FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071068981> ?p ?o ?g. }

• W2071068981 endingPage "414" @default.
• W2071068981 startingPage "407" @default.
• W2071068981 abstract "Objective To report the spectrum of iris lesions based on patient age at presentation. Design Retrospective, nonrandomized, single-center case series. Participants We included 3680 iris tumors in 3451 patients. Methods Chart review. Main Outcome Measures Diagnostic category based on age. Results The mean age at presentation was 48 years and there were 449 (12%) tumors in children (≤20 years), 788 (21%) in young adults (21–40 years), 1308 (36%) in mid adults (41–60 years), and 1135 (31%) in senior adults (>60 years). Of 3680 tumors, the diagnostic category was cystic (n = 768; 21%) or solid (n = 2912; 79%). The cystic tumors originated from iris pigment epithelium (IPE; n = 672; 18%) or iris stroma (n = 96; 3%). The solid tumors included melanocytic (n = 2510; 68%) and nonmelanocytic (n = 402; 11%). The melanocytic tumors comprised nevus (n = 1503; 60%), melanocytoma (n = 68; 3%), melanoma (n = 645; 26%), and melanocytosis (n = 64; 3%). Of 2510 melanocytic tumors, the first and second most common diagnoses by age (children, young adult, mid adult, senior adult) were nevus (53%, 57%, 63%, and 63%, respectively) and melanoma (17%, 27%, 26%, and 27%, respectively). The nonmelanocytic tumors included categories of choristomatous (n = 4; <1%), vascular (n = 57; 2%), fibrous (n = 2; <1%), neural (n = 3; <1%), myogenic (n = 2;, <1%), epithelial (n = 35; 1%), xanthomatous (n = 8; <1%), metastasis (n = 67; 2%), lymphoid (n = 12; <1%), leukemic (n = 2; <1%), secondary (n = 12; <1%), and nonneoplastic simulators (n = 198; 5%). The median age (in years) at diagnosis included cystic (39), melanocytic (52), choristomatous (0.7), vascular (56), fibrous (53), neural (8), myogenic (42), epithelial (63), xanthomatous (1.9), metastasis (60), lymphoid (57), leukemic (25.5), secondary (59), and nonneoplastic simulators (49). Overall, the 3 most common specific diagnoses (children, young adult, mid adult, senior adult) were nevus (25%, 36%, 47%, and 47%, respectively), IPE cyst (28%, 30%, 15%, and 14%, respectively), and melanoma (8%, 16%, 20%, and 19%, respectively). Conclusions In an ocular oncology practice, the spectrum of iris tumors includes cystic (21%) and solid (79%) tumors. The solid tumors were melanocytic (68%) or nonmelanocytic (11%). At all ages, the most common specific diagnoses were nevus (42%), IPE cyst (19%), and melanoma (17%). Financial Disclosure(s) The authors have no proprietary or commercial interest in any of the materials discussed in this article. To report the spectrum of iris lesions based on patient age at presentation. Retrospective, nonrandomized, single-center case series. We included 3680 iris tumors in 3451 patients. Chart review. Diagnostic category based on age. The mean age at presentation was 48 years and there were 449 (12%) tumors in children (≤20 years), 788 (21%) in young adults (21–40 years), 1308 (36%) in mid adults (41–60 years), and 1135 (31%) in senior adults (>60 years). Of 3680 tumors, the diagnostic category was cystic (n = 768; 21%) or solid (n = 2912; 79%). The cystic tumors originated from iris pigment epithelium (IPE; n = 672; 18%) or iris stroma (n = 96; 3%). The solid tumors included melanocytic (n = 2510; 68%) and nonmelanocytic (n = 402; 11%). The melanocytic tumors comprised nevus (n = 1503; 60%), melanocytoma (n = 68; 3%), melanoma (n = 645; 26%), and melanocytosis (n = 64; 3%). Of 2510 melanocytic tumors, the first and second most common diagnoses by age (children, young adult, mid adult, senior adult) were nevus (53%, 57%, 63%, and 63%, respectively) and melanoma (17%, 27%, 26%, and 27%, respectively). The nonmelanocytic tumors included categories of choristomatous (n = 4; <1%), vascular (n = 57; 2%), fibrous (n = 2; <1%), neural (n = 3; <1%), myogenic (n = 2;, <1%), epithelial (n = 35; 1%), xanthomatous (n = 8; <1%), metastasis (n = 67; 2%), lymphoid (n = 12; <1%), leukemic (n = 2; <1%), secondary (n = 12; <1%), and nonneoplastic simulators (n = 198; 5%). The median age (in years) at diagnosis included cystic (39), melanocytic (52), choristomatous (0.7), vascular (56), fibrous (53), neural (8), myogenic (42), epithelial (63), xanthomatous (1.9), metastasis (60), lymphoid (57), leukemic (25.5), secondary (59), and nonneoplastic simulators (49). Overall, the 3 most common specific diagnoses (children, young adult, mid adult, senior adult) were nevus (25%, 36%, 47%, and 47%, respectively), IPE cyst (28%, 30%, 15%, and 14%, respectively), and melanoma (8%, 16%, 20%, and 19%, respectively). In an ocular oncology practice, the spectrum of iris tumors includes cystic (21%) and solid (79%) tumors. The solid tumors were melanocytic (68%) or nonmelanocytic (11%). At all ages, the most common specific diagnoses were nevus (42%), IPE cyst (19%), and melanoma (17%)." @default.
• W2071068981 created "2016-06-24" @default.
• W2071068981 creator A5001760520 @default.
• W2071068981 creator A5016540186 @default.
• W2071068981 creator A5032463933 @default.
• W2071068981 creator A5035178528 @default.
• W2071068981 creator A5040247973 @default.
• W2071068981 creator A5041297650 @default.
• W2071068981 creator A5043721425 @default.
• W2071068981 creator A5048440913 @default.
• W2071068981 creator A5053984461 @default.
• W2071068981 creator A5066304115 @default.
• W2071068981 creator A5069149243 @default.
• W2071068981 creator A5072554691 @default.
• W2071068981 creator A5080730323 @default.
• W2071068981 creator A5080759482 @default.
• W2071068981 creator A5084548739 @default.
• W2071068981 date "2012-02-01" @default.
• W2071068981 modified "2023-10-01" @default.
• W2071068981 title "Clinical Survey of 3680 Iris Tumors Based on Patient Age at Presentation" @default.
• W2071068981 cites W123314342 @default.
• W2071068981 cites W1916834818 @default.
• W2071068981 cites W1996444647 @default.
• W2071068981 cites W2000741939 @default.
• W2071068981 cites W2012517837 @default.
• W2071068981 cites W2016503685 @default.
• W2071068981 cites W2031965754 @default.
• W2071068981 cites W2051660946 @default.
• W2071068981 cites W2066241066 @default.
• W2071068981 cites W2077318298 @default.
• W2071068981 cites W2097741397 @default.
• W2071068981 cites W2102712469 @default.
• W2071068981 cites W2114468382 @default.
• W2071068981 cites W2146971762 @default.
• W2071068981 cites W2150922673 @default.
• W2071068981 cites W2151222138 @default.
• W2071068981 cites W2155073317 @default.
• W2071068981 cites W2603456490 @default.
• W2071068981 cites W4240043508 @default.
• W2071068981 cites W4247066878 @default.
• W2071068981 cites W93316001 @default.
• W2071068981 doi "https://doi.org/10.1016/j.ophtha.2011.07.059" @default.
• W2071068981 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22035581" @default.
• W2071068981 hasPublicationYear "2012" @default.
• W2071068981 type Work @default.
• W2071068981 sameAs 2071068981 @default.
• W2071068981 citedByCount "117" @default.
• W2071068981 countsByYear W20710689812012 @default.
• W2071068981 countsByYear W20710689812013 @default.
• W2071068981 countsByYear W20710689812014 @default.
• W2071068981 countsByYear W20710689812015 @default.
• W2071068981 countsByYear W20710689812016 @default.
• W2071068981 countsByYear W20710689812017 @default.
• W2071068981 countsByYear W20710689812018 @default.
• W2071068981 countsByYear W20710689812019 @default.
• W2071068981 countsByYear W20710689812020 @default.
• W2071068981 countsByYear W20710689812021 @default.
• W2071068981 countsByYear W20710689812022 @default.
• W2071068981 countsByYear W20710689812023 @default.
• W2071068981 crossrefType "journal-article" @default.
• W2071068981 hasAuthorship W2071068981A5001760520 @default.
• W2071068981 hasAuthorship W2071068981A5016540186 @default.
• W2071068981 hasAuthorship W2071068981A5032463933 @default.
• W2071068981 hasAuthorship W2071068981A5035178528 @default.
• W2071068981 hasAuthorship W2071068981A5040247973 @default.
• W2071068981 hasAuthorship W2071068981A5041297650 @default.
• W2071068981 hasAuthorship W2071068981A5043721425 @default.
• W2071068981 hasAuthorship W2071068981A5048440913 @default.
• W2071068981 hasAuthorship W2071068981A5053984461 @default.
• W2071068981 hasAuthorship W2071068981A5066304115 @default.
• W2071068981 hasAuthorship W2071068981A5069149243 @default.
• W2071068981 hasAuthorship W2071068981A5072554691 @default.
• W2071068981 hasAuthorship W2071068981A5080730323 @default.
• W2071068981 hasAuthorship W2071068981A5080759482 @default.
• W2071068981 hasAuthorship W2071068981A5084548739 @default.
• W2071068981 hasConcept C126322002 @default.
• W2071068981 hasConcept C141071460 @default.
• W2071068981 hasConcept C16005928 @default.
• W2071068981 hasConcept C167135981 @default.
• W2071068981 hasConcept C205545832 @default.
• W2071068981 hasConcept C2777601897 @default.
• W2071068981 hasConcept C2777658100 @default.
• W2071068981 hasConcept C2779323059 @default.
• W2071068981 hasConcept C2910954120 @default.
• W2071068981 hasConcept C502942594 @default.
• W2071068981 hasConcept C71924100 @default.
• W2071068981 hasConceptScore W2071068981C126322002 @default.
• W2071068981 hasConceptScore W2071068981C141071460 @default.
• W2071068981 hasConceptScore W2071068981C16005928 @default.
• W2071068981 hasConceptScore W2071068981C167135981 @default.
• W2071068981 hasConceptScore W2071068981C205545832 @default.
• W2071068981 hasConceptScore W2071068981C2777601897 @default.
• W2071068981 hasConceptScore W2071068981C2777658100 @default.
• W2071068981 hasConceptScore W2071068981C2779323059 @default.
• W2071068981 hasConceptScore W2071068981C2910954120 @default.
• W2071068981 hasConceptScore W2071068981C502942594 @default.
• W2071068981 hasConceptScore W2071068981C71924100 @default.
• W2071068981 hasIssue "2" @default.

• next